Depression<unk>  is primarily used for major depressive disorder and other mood disorders. Onset of action appears faster than some selective serotonin reuptake inhibitors (SSRI) and similar to tricyclic antidepressants. In 2010, NICE recommended generic SSRIs as first line choices, as they are "equally effective as other antidepressants and have a favourable risk–benefit ratio." With respect to<unk> , it found: "There is no difference between<unk>  and other antidepressants on any efficacy measure, although in terms of achieving remission<unk>  appears to have a statistical though not clinical advantage. In addition,<unk>  has a statistical advantage over selective serotonin reuptake inhibitors in terms of reducing symptoms of depression, but the difference is not clinically important. However, there is strong evidence that patients taking<unk>  are less likely to leave treatment early because of side effects, although this is not the case for patients reporting side effects or leaving treatment early for any reason." A 2011 Cochrane review that compared<unk>  to other antidepressants found that, while it appears to have a faster onset in people for whom it works (measured at two weeks), its efficacy is about the same as other antidepressants after six weeks' use. A 2012 review focused on antidepressants and sleep found that in many people with sleep disorders caused by depression,<unk>  reduces the time it takes to fall asleep and increases the quality of sleep, but that in some people it can disturb sleep, especially at higher doses, causing restless leg syndrome in 8 to 28% of people and in rare cases causes REM sleep behavior disorder. This seemingly paradoxical dose–response curve of<unk>  with respect to somnolence is owed to the exceptionally high affinity of the drug for the histamine H1, 5-HT2A, and 5-HT2C receptors; exhibiting near exclusive occupation of these receptors at doses ≤15 mg. However, at higher doses, inverse antagonism and constitutive activation of the α2A-, α2B-, and α2C-adrenergic receptors begins to offset activity at H1 receptors leading to decreased sonomolence and even a subjective sensation of "activation" in treated patients. A 2018 analysis of 21 antidepressants found them to be fairly similar overall. It found tentative evidence for<unk>  being in the more effective group and middle in tolerability. After one week of usage,<unk>  was found to have an earlier onset of action compared to SSRIs. Other There is also some evidence supporting its use in treating the following conditions, for which it is sometimes prescribed off-label: * Generalized anxiety disorder * Social anxiety disorder * Obsessive–compulsive disorder * Panic disorder * Post-traumatic stress disorder * Low appetite/underweight * Insomnia * Nausea and vomiting * Itching * Headaches and migraine Doses of<unk>  used for sleep range from 7.5 to 45 mg. Doses of 7.5 to 15 mg are recommended as<unk>  may become more stimulating at higher doses.
Mirtazapine
Sertraline
Citalopram
Fluparoxan
Quetiapine
Asenapine
Loxapine
Escitalopram